Associated Papers
USP3 promotes DNA damage response and chemotherapy resistance through stabilizing and deubiquitinating SMARCA5 in prostate cancer.
Li S et al.
Cell Death & Disease, 2024
USP3: Key deubiquitylation enzyme in human diseases.
Zhang H et al.
Cancer Science, 2024
An ALYREF-MYCN coactivator complex drives neuroblastoma tumorigenesis through effects on USP3 and MYCN stability.
Nagy Z et al.
Nature Communications, 2021
Deubiquitinating enzyme USP3 controls CHK1 chromatin association and activation.
Cheng YC et al.
Proceedings of the National Academy of Sciences of the United States of America, 2018
USP3 stabilizes p53 protein through its deubiquitinase activity.
Fu S et al.
Biochemical and Biophysical Research Communications, 2017
USP3 inhibits type I interferon signaling by deubiquitinating RIG-I-like receptors.
Cui J et al.
Cell Research, 2014
Human RNF169 is a negative regulator of the ubiquitin-dependent response to DNA double-strand breaks.
Poulsen M et al.
The Journal of Cell Biology, 2012
Defining the human deubiquitinating enzyme interaction landscape.
Sowa ME et al.
Cell, 2009
RNF168 binds and amplifies ubiquitin conjugates on damaged chromosomes to allow accumulation of repair proteins.
Doil C et al.
Cell, 2009
Human USP3 is a chromatin modifier required for S phase progression and genome stability.
Nicassio F et al.
Current Biology : Cb, 2007
Select a paper to view details